ClinicalTrials.gg
CompletedNCT03496662Updated Jul 29, 2025Results posted

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

A Phase 1/2 interventional study of BMS-813160 and Nivolumab in Pancreatic Ductal Adenocarcinoma, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Washington University School of Medicine · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.

02

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
03

In context

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced or borderline resectable pancreatic ductal adenocarcinoma. Patients with clinical suspicion of pancreatic adenocarcinoma can be enrolled for pre-treatment , and must be histologically confirmed to have adenocarcinoma before being treated on study. Patients with squamous carcinoma, adenosquamous carcinoma or neuroendocrine tumor will be excluded. Tumor Biopsy can be omitted, if deemed by PI and treatment physician, that it may incur immediate, excessive health risks to patients. This determination (rationale and discussion with PI and treating physician) should be clearly documented in the screening visit notes.
  • defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan or MRI.
  • At least 18 years of age.
  • performance status ≤ 1
  • Normal bone marrow and organ function as defined below:

    • Leukocytes ≥ 2,000/mcL
    • ≥ 1,500/mcl
    • ≥ 8.5 g/dL
    • ≥ 100,000/mcl
    • Total ≤ 1.5 x IULN (except participants with Gilbert's Syndrome who must have normal direct bilirubin)
    • (SGOT)/ALT(SGPT) ≤ 3 x IULN
    • Serum albumin ≥ 3g/dL
    • Creatinine ≤ 1.5 x IULN OR ≥ 40 mL/min by Cockcroft-Gault for patients with creatinine levels above institutional normal
  • Women of and men must agree to use at least two forms of (hormonal, barrier method of birth control, abstinence, and must include barrier method) prior to study entry, for the duration of study participation, and through 5 months (for women) or 7 months (for men) after the last dose of treatment on this study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Able to understand and willing to sign an IRB approved written document.
  • All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 (National Cancer Institute [NCI CTCAE] v5.0) or baseline before administration of study treatment. Participants with toxicities attributed to prior anti-cancer therapy that are not expected to resolve and result in long lasting sequelae, such as neuropathy after platinum-based therapy, are permitted to enroll.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to chemotherapy or radiation for the disease to be treated on this trial not allowed.
  • Previous (except non-melanoma skin cancers, and in situ bladder, gastric, colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period. Other active malignancy requiring concurrent intervention
  • Currently receiving any other agents, or exposure to any investigational drug or placebo within 4 weeks of study treatment
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BMS-813160, nivolumab, gemcitabine, paclitaxel, nab-paclitaxel, or other agents used in the study.
  • Prior exposure to , anti-PD-L1, CCR2/5, or anti-CTLA4 antibodies.
  • Taking immunomodulatory agents (including and NSAIDs). A of at least 4 weeks or 5 half-lives, whichever is shorter, is required for patients receiving immunomodulatory agents at the time of enrollment.

Note: daily use of low dose aspirin (e.g. 81 mg PO QD) is not considered an immunomodulatory agent and patients are still eligible for enrollment despite taking such medication at a low dose

  • Participants with active, known or suspected disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, euthyroid participants with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study treatment), psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll after discussing with the Principal Investigator
  • Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other medications within 14 days of study treatment except for adrenal replacement steroid doses > 10 mg daily prednisone equivalent in the absence of active autoimmune disease. Note: treatment with a short course of steroids (\< 5 days) up to 7 days prior to initiating study treatment is permitted.
  • History of allogeneic organ or stem cell transplant.
  • Pregnant and/or breastfeeding. Women of must have a negative pregnancy test within 14 days of study entry and again within 24 hours prior to first treatment.
  • Known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (by PCR).
  • Known history of testing positive for (HIV) or known acquired immunodeficiency syndrome. Anti-retroviral agents are known to have potential adverse pharmacokinetic interactions with nivolumab and/or BMS-813160. IN addition, patients not on anti-retroviral agents, regardless of HIV viral load, are at increased risk of lethal infections with marrow-suppressive therapy including chemotherapy. Testing for HIV must be performed at sites mandated by local requirements.
  • Requires continued use of warfarin for anticoagulation and cannot stop warfarin or be safely switched to another anticoagulant.
  • Current or recent (within 3 months of study treatment administration) gastrointestinal disease or conditions that could interfere with the swallowing or absorption of study medication or inability to tolerate oral medication.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral anti-bacterial, anti-viral, or anti-fungal therapy ≤ 7 days prior to administration of study medication; immunosuppression; autoimmune conditions; underlying pulmonary disease; or psychiatric illness/social situations that would limit compliance with study requirements.
  • Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity.
  • Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:

    • Myocardial infarction or stroke/ within the past 6 months
    • Uncontrolled angina within the past 3 months
    • Any history of arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
    • corrected for heart rate using Fridericia's formula (QTcF) prolongation > 480 msec
    • History of other clinically significant heart disease (e.g. cardiomyopathy, congestive heart failure with functional classification III-IV, pericarditis, significant pericardial effusion, or myocarditis)
  • Major surgery within 28 days prior to the first study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment.
  • Concurrent use of oral or intravenous medications or food which may interfere with BMS-813160 including any strong inhibitors or inducers of or P-gp is not allowed. These include but are not limited to Class I antiarrhythmics (eg, quinidine, procainamide, dysopiramide, lidocaine, phenytoin, mexiletine, tocainide, flecainide, propafenone, moricizine), Grapefruit and Seville oranges.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Part A - Experimental Dose Level 0

    * BMS-813160 300 mg twice per day * Nivolumab 30-minute intravenous (IV) infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle * Gemcitabine 30-minute IV infusion 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle * Nab-paclitaxel 30-40-minute IV infusion 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle * Post-treatment biopsy at the end of cycle 2 * Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cyclesore cycles

    Drug: BMS-813160 · Drug: Nivolumab · Drug: Gemcitabine · Drug: Nab-paclitaxel · Procedure: Biopsy · Procedure: Peripheral blood

  • Active comparator
    Part A - Control (chemotherapy only)

    * Gemcitabine 30-minute IV infusion 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle Nab-paclitaxel 30-40-minute IV infusion 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle * Post treatment biopsy at the end of cycle 2 * Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles

    Drug: Gemcitabine · Drug: Nab-paclitaxel · Procedure: Biopsy · Procedure: Peripheral blood

  • Experimental
    Part B - Dose expansion

    * BMS-813160 300 mg twice per day * Nivolumab 30-minute IV infusion at a flat dose of 480 mg on Day 1 of each 28-day cycle * Gemcitabine 30-minute IV infusion 1000 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle * Nab-paclitaxel 30-40-minute IV infusion 125 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle * Post-treatment biopsy at the end of cycle 2 * Patients who achieve stable disease, a partial response, or complete response after the first 2 cycles of treatment will continue to receive 2 more cycles of treatment followed by a restaging scan. Patients thought to have pseudo-progression will continue to receive treatment for 2 more cycles

    Drug: BMS-813160 · Drug: Nivolumab · Drug: Gemcitabine · Drug: Nab-paclitaxel · Procedure: Biopsy · Procedure: Peripheral blood

Interventions

  • BMS-813160 will be supplied by Bristol Myers Squibb

  • Nivolumab will be supplied by Bristol Myers Squibb

    Also known as: Opdivo

  • Gemcitabine will be given as per routine care from commercial supply.

    Also known as: Gemzar

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nab-paclitaxel will be given as per routine care from commercial supply.

    Also known as: Abraxane

  • ProcedureBiopsy

    Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery

  • ProcedurePeripheral blood

    -Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)

06

What researchers measure

Primary outcomes

  1. (Part A Experimental Dose Level 0 Only) Safety of the Combination of BMS-813160 Plus Nivolumab Plus Gemcitabine Plus Nab-paclitaxel as Measured by Frequency, Type, and Severity of Adverse Events

    -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.

    Time frame: Through 100 days after completion of treatment (approximately 7.5 months)

  2. (Part B and Part A Experimental Dose Level 0 Only): Objective Response Rate

    * Objective response rate (ORR) is defined as number of participants with complete response or partial response. * Complete Response (CR): Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Normalization of tumor marker level. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Through completion of treatment (approximately 4 months)

Secondary outcomes

  1. (Part B and Part A Experimental Dose Level 0 Only): Percentage of Patients Whose Disease Becomes Resectable After Treatment

    Time frame: Completion of treatment (approximately 4 months)

  2. (Part B and Part A Experimental Dose Level 0 Only): Progression-free Survival (PFS)

    * PFS is defined as the days from the date of treatment and death or progression, which occurs first. Patients alive without progression or lost to follow-up are censored at the last follow-up. * Progressive disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: Through completion of follow-up (median length of follow-up 12.15 months, full range 0.43-44.10 months)

  3. (Part B and Part A Experimental Dose Level 0 Only): Overall Survival (OS)

    OS is defined as days from date of treatment to date of death. Patients alive or lost to follow-up are censored at the last follow-up.

    Time frame: Through completion of follow-up (median length of follow-up 17.63 months, full range 0.43-64.47 months)

07

Results

Posted Nov 30, 2022

Participant flow

Participant flow — Overall Study
MilestonePart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
Started7825
Completed6816
Not completed109
Withdrew: Adverse event004
Withdrew: Withdrawal by subject102
Withdrew: Death002
Withdrew: Noncompliance001

Outcome measures

Primary(Part A Experimental Dose Level 0 Only) Safety of the Combination of BMS-813160 Plus Nivolumab Plus Gemcitabine Plus Nab-paclitaxel as Measured by Frequency, Type, and Severity of Adverse Events

-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.

Time frame:
Through 100 days after completion of treatment (approximately 7.5 months)
Reported as:
Count of participants · Participants
(Part A Experimental Dose Level 0 Only) Safety of the Combination of BMS-813160 Plus Nivolumab Plus Gemcitabine Plus Nab-paclitaxel as Measured by Frequency, Type, and Severity of Adverse Events
ParticipantsPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
Grade 1-2 anemia6——
Grade 3 anemia1——
Grade 1-2 leukocytosis1——
Grade 1-2 abdominal pain2——
Grade 1-2 constipation3——
Grade 1-2 diarrhea2——
Grade 3 diarrhea1——
Grade 1-2 hemorrhoids1——
Grade 1-2 mucositis oral2——
Grade 1-2 nausea6——
Grade 4 upper gastrointestinal hemorrhage1——
Grade 1-2 vomiting3——
Grade 1-2 chills3——
Grade 1-2 edema limbs5——
Grade 1-2 fatigue3——
Grade 3 fatigue3——
Grade 1-2 fever4——
Grade 1-2 foot pain1——
Grade 1-2 sweating2——
Grade 1-2 activated partial thromboplastin time prolonged1——
Grade 1-2 alanine aminotransferase increased4——
Grade 3 alanine aminotransferase increased2——
Grade 1-2 alkaline phosphatase increased4——
Grade 3 alkaline phosphatase increased1——
Grade 1-2 aspartate aminotransferase increased4——
Grade 3 aspartate aminotransferase increased2——
Grade 1-2 creatinine increased2——
Grade 1-2 lymphocyte count decreased3——
Grade 3 lymphocyte count decreased3——
Grade 1-2 neutrophil count decreased1——
Grade 3 neutrophil count decreased3——
Grade 4 neutrophil count decreased1——
Grade 1-2 platelet count decreased7——
Grade 1-2 white blood cell decreased3——
Grade 3 white blood cell decreased3——
Grade 1-2 anorexia5——
Grade 1-2 dehydration1——
Grade 1-2 hyperglycemia3——
Grade 3 hyperglycemia1——
Grade 1-2 hypoalbuminemia5——
Grade 1-2 hypocalcemia2——
Grade 1-2 hypoglycemia1——
Grade 1-2 hypokalemia3——
Grade 3 hypokalemia1——
Grade 1-2 hyponatremia1——
Grade 3 hyponatremia1——
Grade 1-2 arthralgia2——
Grade 1-2 back pain1——
Grade 1-2 myalgia3——
Grade 1-2 pain in extremity2——
Grade 1-2 vertigo1——
Grade 1-2 dizziness4——
Grade 1-2 dysgeusia1——
Grade 1-2 headache2——
Grade 1-2 paresthesia1——
Grade 1-2 peripheral sensory neuropathy5——
Grade 1-2 tremor2——
Grade 1-2 depression1——
Grade 1-2 insomnia1——
Grade 1-2 cough5——
Grade 1-2 dyspnea1——
Grade 3 dyspnea1——
Grade 1-2 epistaxis4——
Grade 1-2 hoarseness1——
Grade 1-2 nasal congestion1——
Grade 1-2 pneumonitis1——
Grade 1-2 alopecia7——
Grade 1-2 dermatitis1——
Grade 1-2 discoloration2——
Grade 1-2 nail ridging1——
Grade 1-2 pruritis1——
Grade 1-2 rash maculopapular3——
Grade 1-2 skin hyperpigmentation1——
Grade 1-2 acute kidney injury1——
Grade 1-2 dysuria1——
Grade 1-2 hematuria1——
Grade 1-2 proteinuria1——
Grade 3 cholangitis1——
Grade 1-2 cholecystitis1——
Grade 3 gallbladder obstruction1——
Grade 1-2 hypertension1——
Grade 3 hypertension2——
Grade 1-2 hypotension2——
Grade 1-2 thromboembolic event1——
Grade 1-2 chest swelling1——
Grade 1-2 sinus bradycardia2——
Grade 1-2 vaginal bleeding1——
Grade 1-2 bruising1——
Grade 1-2 infusion related reaction1——
Grade 1-2 wound dehiscence1——
Grade 3 sepsis1——
Grade 1-2 gallbladder infection2——
Grade 1-2 upper respiratory infection1——
Primary(Part B and Part A Experimental Dose Level 0 Only): Objective Response Rate

* Objective response rate (ORR) is defined as number of participants with complete response or partial response. * Complete Response (CR): Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Normalization of tumor marker level. * Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Through completion of treatment (approximately 4 months)
Reported as:
Count of participants · Participants
(Part B and Part A Experimental Dose Level 0 Only): Objective Response Rate
ParticipantsPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
(Part B and Part A Experimental Dose Level 0 Only): Objective Response Rate1—6
Secondary(Part B and Part A Experimental Dose Level 0 Only): Percentage of Patients Whose Disease Becomes Resectable After Treatment
Time frame:
Completion of treatment (approximately 4 months)
Reported as:
Count of participants · Participants
(Part B and Part A Experimental Dose Level 0 Only): Percentage of Patients Whose Disease Becomes Resectable After Treatment
ParticipantsPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
(Part B and Part A Experimental Dose Level 0 Only): Percentage of Patients Whose Disease Becomes Resectable After Treatment2—11
Secondary(Part B and Part A Experimental Dose Level 0 Only): Progression-free Survival (PFS)

* PFS is defined as the days from the date of treatment and death or progression, which occurs first. Patients alive without progression or lost to follow-up are censored at the last follow-up. * Progressive disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
Through completion of follow-up (median length of follow-up 12.15 months, full range 0.43-44.10 months)
Reported as:
Mean · months
(Part B and Part A Experimental Dose Level 0 Only): Progression-free Survival (PFS)
monthsPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
(Part B and Part A Experimental Dose Level 0 Only): Progression-free Survival (PFS)13.69 (4.13 to 35.77)—14.00 (0.43 to 44.10)
Secondary(Part B and Part A Experimental Dose Level 0 Only): Overall Survival (OS)

OS is defined as days from date of treatment to date of death. Patients alive or lost to follow-up are censored at the last follow-up.

Time frame:
Through completion of follow-up (median length of follow-up 17.63 months, full range 0.43-64.47 months)
Reported as:
Mean · months
(Part B and Part A Experimental Dose Level 0 Only): Overall Survival (OS)
monthsPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
(Part B and Part A Experimental Dose Level 0 Only): Overall Survival (OS)22.55 (6.37 to 64.47)—20.39 (0.43 to 52.43)

Adverse events

Collected over Adverse events were collected until the date of surgery, or 100 days after the last dose of treatment on study if patients did not have surgery [median treatment length was 112 days (full range 14-161 days). All-cause mortality data was collected until completion of follow-up (median length of follow-up 17.63 months, full range 0.43-64.47 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - Experimental Dose Level 05/7 (71.4%)4/7 (57.1%)7/7 (100%)
Part A - Control (Chemotherapy Only)4/8 (50%)5/8 (62.5%)8/8 (100%)
Part B - Dose Expansion21/25 (84%)17/25 (68%)25/25 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
SepsisInfections and infestations0/72/82/25
Upper gastrointestinal hemorrhageGastrointestinal disorders1/70/80/25
FeverGeneral disorders1/71/81/25
CholecystitisHepatobiliary disorders1/70/81/25
Gallbladder obstructionHepatobiliary disorders1/70/80/25
HypoglycemiaMetabolism and nutrition disorders1/70/80/25
Small intestinal obstructionGastrointestinal disorders0/71/80/25
Creatinine increasedInvestigations0/71/80/25
Rash maculopapularSkin and subcutaneous tissue disorders0/71/80/25
HypotensionVascular disorders0/71/81/25
Most frequent other events
Showing 10 of 140
Most frequent other events
EventPart A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose Expansion
AnemiaBlood and lymphatic system disorders7/74/825/25
Platelet count decreasedInvestigations7/73/818/25
AlopeciaSkin and subcutaneous tissue disorders7/74/818/25
HypoalbuminemiaMetabolism and nutrition disorders5/73/823/25
NauseaGastrointestinal disorders6/71/815/25
FatigueGeneral disorders6/73/820/25
Alanine aminotransferase increasedInvestigations6/74/817/25
Aspartate aminotransferase increasedInvestigations6/74/814/25
White blood cell decreasedInvestigations6/74/817/25
Edema limbsGeneral disorders5/74/812/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose ExpansionTotal
Median71.5 (64 to 78)72 (60 to 74)68 (48 to 81)70 (48 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Part A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose ExpansionTotal
Female64818
Male141722
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose ExpansionTotal
Hispanic or Latino0000
Not Hispanic or Latino782540
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose ExpansionTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1225
White652334
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part A - Experimental Dose Level 0Part A - Control (Chemotherapy Only)Part B - Dose ExpansionTotal
United States782540
08

Study locations

1 site
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2021, 37 months.

Results were first posted in Nov 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 12, 2018
StartActual
Aug 31, 2018
Primary completionActual
Oct 28, 2021
CompletionActual
Jul 25, 2024
Results first posted
Nov 30, 2022
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03496662
Collaborators
Bristol-Myers Squibb, The Foundation for Barnes-Jewish Hospital, National Institutes of Health (NIH), National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Aug 31, 2018
Primary completion
Oct 28, 2021
Completion
Jul 25, 2024
Results posted
Nov 30, 2022
Last update
Jul 29, 2025

Study contacts

Kian-Huat Lim, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-813160

Start the discussion